Lung Carcinoma

  • Claire W. MichaelEmail author


Lung carcinoma remains the most common source of malignant effusions. A malignant effusion would upstage a lung tumor of any size to stage IV and significantly affect the treatment modality. It may also be the first manifestation of the disease, and a definitive diagnosis can spare the patient additional more morbid diagnostic procedures. This chapter reviews the epidemiology, the clinical presentation, and the morphologic features diagnostic of adenocarcinoma, squamous cell carcinoma, and small cell carcinoma. The differential diagnoses and diagnostic pitfalls are discussed in detail along with the utilization of ancillary techniques, particularly the up-to-date immunohistochemical stains relevant for establishing a definitive diagnosis.


  1. 1.
    Ferlay J, Soerjonataram I, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. GLOBOCAN 2012 v1.1 cancer incidence and mortality worldwide: IARC CancerBase No. 11 [Internet]. Lyon: International Agency for Research on Cancer; 2014. Accessed 16 Jan 2015.Google Scholar
  2. 2.
    Howlader N, Noone AM, Krapcho M, Miller D, Bishop K, Kosary CL, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Fewer EJ, Cronin KA, editors. SEER cancer statistics review, 1975–2014, Bethasda, MD: National Cancer Institute., bases on November 2016 SEER data submission, posted to the SEER web site, April 2017.
  3. 3.
    Parkin DM, Muir CS. Cancer incidence in five continents. Comparability and quality of data. IARC Sci Publ. 1992;120:45–173.Google Scholar
  4. 4.
    Travis WD, Brambilla E, Burke A, Marx A, Nicholson AG. WHO classification of tumours of the lung, pleura, thymus and heart. In: Travis WD, Brambilla E, Burke AP, Marx A, Nicholson AG, editors. Pathology and genetics of tumours of the lung, pleura, thymus and heart. 4th ed. Lyon: IARC Press; 2015.Google Scholar
  5. 5.
    Porcel JM, Esquerda A, Vives M, Bilsa S. Etiology of pleural effusion: analysis of more than 3,000 consecutive thoracenteses. Arch Bronconeumol. 2014;50:161–5.CrossRefPubMedGoogle Scholar
  6. 6.
    Porcel JM, Gasol A, Bielsa S, Civit C, Light RW, Salud A. Clinical features and survival of lung cancer patients with pleural effusions. Respirology. 2015;20:654–9.CrossRefPubMedGoogle Scholar
  7. 7.
    Johnston WW. The malignant pleural effusion. A review of cytopathologic diagnoses of 584 specimens from 472 consecutive patients. Cancer. 1985;56:905–9.CrossRefPubMedGoogle Scholar
  8. 8.
    DiBonito L, Falconieri G, Colautti I, Bonifacio D, Dudine S. The positive pleural effusion. A retrospective study of cytopathologic diagnoses with autopsy confirmation. Acta Cytol. 1992;36:329–32.PubMedGoogle Scholar
  9. 9.
    Renshaw AA, Madge R, Sugarbaker DJ, Swanson S. Malignant pleural effusions after resection of pulmonary adenocarcinoma. Acta Cytol. 1998;42:1111–5.CrossRefPubMedGoogle Scholar
  10. 10.
    Light RW, Hamm H. Malignant pleural effusion: would the real cause please stand up? Eur Respir J. 1997;112:242S–8S.Google Scholar
  11. 11.
    Eberhardt WE, Mitchell A, Crowley L, et al. The IASLC lung cancer staging project: proposals for the revisions of the M descriptors in the forthcoming eighth edition of the TNM classification of lung cancer. J Thorac Oncol. 2015;10(110):1515–22.CrossRefPubMedGoogle Scholar
  12. 12.
    Rami-Porta R, Asamura H, Travis WD, Rusch VW. Lung. In: Amin MB, editor. AJCC cancer staging manual. 8th ed. Cham: Springer; 2017.Google Scholar
  13. 13.
    Lombardi G, Zustovich F, Nicoletto MO, Donach M, Artioli G, Pastorelli D. Diagnosis and treatment of malignant pleural effusion: a systematic literature review and new approaches. Am J Clin Oncol. 2010;33:420–3.CrossRefPubMedGoogle Scholar
  14. 14.
    Leung AN, Muller NL, Miller RR. CT in differential diagnosis of diffuse pleural disease. AJR Am J Roentgenol. 1990;154:487–92.CrossRefPubMedGoogle Scholar
  15. 15.
    Azzopardi M, Porcel JM, Koegelenberg CF, Lee YCG, Fysh ETH. Current controversies in the management of malignant pleural effusions. Semin Respir Crit Care Med. 2014;35:723–31.CrossRefPubMedGoogle Scholar
  16. 16.
    Yoneda KY, Mathur PN, Gasparini S. The evolving role of interventional pulmonary in the interdisciplinary approach to the staging and management of lung cancer: Part III: diagnosis and management of malignant pleural effusions. Clin Lung Cancer. 2007;8(9):535–47.CrossRefPubMedGoogle Scholar
  17. 17.
    Ozcakar B, Martinez CH, Morice RC, et al. Does pleural fluid appearance really matter? The relationship between fluid appearance and cytology, cell counts, and chemical laboratory measurements in pleural effusions of patients with cancer. J Cardiothorac Surg. 2010;5:63.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Heffner JE, Klein JS. Recent advances in the diagnosis and management of malignant pleural effusions. Mayo Clin Proc. 2008;83:235–50.CrossRefPubMedGoogle Scholar
  19. 19.
    Kimura M, Tojo T, Naito H, Nagata Y, Kawai N, Taniguchi S. Effects of a simple intraoperative intrathoracic hyperthermotherapy for lung cancer with malignant pleural effusion or dissemination. Interact Cardiovasc Thorac Surg. 2010;10:568–71.CrossRefPubMedGoogle Scholar
  20. 20.
    Sahn SA. Pleural effusion in lung cancer. Clin Chest Med. 1982;3:443–52.PubMedGoogle Scholar
  21. 21.
    Bedrossian CWM, editor. Malignant effusions: a multimodal approach to cytologic diagnosis. New York: Igaku-Shoin; 1994.Google Scholar
  22. 22.
    Tao LC, editor. Cytopathology of malignant effusions. Chicago: ASCP Press; 1996.Google Scholar
  23. 23.
    Michael CW, Bedrossian CWM, Chhieng D. Effusion cytology. In: Michael CW, editor. Papanicolaou society of cytopathology monograph series. New York, NY: Cambridge University Press; 2015.Google Scholar
  24. 24.
    Tang P, Vatsia SK, Teichberg S, Kahn E. Pulmonary adenocarcinoma simulating malignant mesothelioma. Arch Pathol Lab Med. 2001;125:1598–600.PubMedGoogle Scholar
  25. 25.
    Kaur G, Nijhawan R, Gupta N, Singh N, Rajwanshi A. Pleural fluid cytology samples in cases of suspected lung cancer: an experience from tertiary care center. Diagn Cytopathol. 2017;45:195–201.CrossRefPubMedGoogle Scholar
  26. 26.
    Cibas ES, Corson JM, Pinkus GS. The distinction of adenocarcinoma from malignant mesothelioma in cell blocks of effusions: the role of routine mucin histochemistry and immunohistochemical assessment of carcinoembryonic antigen, keratin proteins, epithelial membrane antigen, and milk fat globule-derived antigen. Hum Pathol. 1987;18:67–74.CrossRefPubMedGoogle Scholar
  27. 27.
    Shield PW, Callan JJ, Devine PL. Markers for metastatic adenocarcinoma in serous effusion specimens. Diagn Cytopathol. 1994;11:237–45.CrossRefPubMedGoogle Scholar
  28. 28.
    Fetsch PA, Abati A. Immunocytochemistry in effusion cytology: a contemporary review. Cancer. 2001;93:293–308.CrossRefPubMedGoogle Scholar
  29. 29.
    Westfall DE, Fan X, Marchevsky AM. Evidence-based guidelines to optimize the selection of antibody panels in cytopathology: pleural effusions with malignant epithelioid cells. Diagn Cytopathol. 2010;38:9–14.PubMedPubMedCentralGoogle Scholar
  30. 30.
    Lozano MD, Panizo A, Toledo GR, Sola JJ, Pardo-Mindan J. Immunocytochemistry in the differential diagnosis of serous effusions: a comparative evaluation of eight monoclonal antibodies in Papanicolaou stained smears. Cancer. 2001;93:68–72.CrossRefPubMedGoogle Scholar
  31. 31.
    Ordonez NG. Role of immunohistochemistry in differentiating epithelial mesothelioma from adenocarcinoma. Review and update. Am J Clin Pathol. 1999;112:75–89.CrossRefPubMedGoogle Scholar
  32. 32.
    Maguire B, Whitaker D, Carrello S, Spagnolo D. Monoclonal antibody Ber-EP4: its use in the differential diagnosis of malignant mesothelioma and carcinoma in cell blocks of malignant effusions and FNA specimens. Diagn Cytopathol. 1994;10:130–4.CrossRefPubMedGoogle Scholar
  33. 33.
    Lv M, Leng J-H, Hao Y-Y, Sun Y, Cha N, Wu G-P. Expression and significance of MOC-31 and calretinin in pleural fluid of patients with lung cancer. Diagn Cytopathol. 2015;43:527–31.CrossRefPubMedGoogle Scholar
  34. 34.
    Comin CE, Novelli L, Boddi V, Paglierani M, Dini S. Calretinin, thrombomodulin, CEA, and CD15: a useful combination of immunohistochemical markers for differentiating pleural epithelial mesothelioma from peripheral pulmonary adenocarcinoma. Hum Pathol. 2001;32:529–36.CrossRefPubMedGoogle Scholar
  35. 35.
    Riera JR, Astengo-Osuna C, Longmate JA, Battifora H. The immunohistochemical diagnostic panel for epithelial mesothelioma: a reevaluation after heat-induced epitope retrieval. Am J Surg Pathol. 1997;21:1409–19.CrossRefPubMedGoogle Scholar
  36. 36.
    Noguchi M, Nakajima T, Hirohashi S, Akiba T, Shimosato Y. Immunohistochemical distinction of malignant mesothelioma from pulmonary adenocarcinoma with anti-surfactant apoprotein, anti-Lewisa, and anti-Tn antibodies. Hum Pathol. 1989;20:53–7.CrossRefPubMedGoogle Scholar
  37. 37.
    Fetsch PA, Abati A, Hijazi YM. Utility of the antibodies CA 19–9, HBME-1, and thrombomodulin in the diagnosis of malignant mesothelioma and adenocarcinoma in cytology. Cancer. 1998;84:101–8.CrossRefPubMedGoogle Scholar
  38. 38.
    Simsir A, Fetsch P, Mehta D, Zakowski M, Abati A. E-cadherin, N-cadherin, and calretinin in pleural effusions: the good, the bad, the worthless. Diagn Cytopathol. 1999;20:125–30.CrossRefPubMedGoogle Scholar
  39. 39.
    Han AC, Filstein MR, Hunt JV, Soler AP, Knudsen KA, Salazar H. N-cadherin distinguishes pleural mesotheliomas from lung adeno-carcinomas: a ThinPrep immunocytochemical study. Cancer. 1999;87:83–6.CrossRefPubMedGoogle Scholar
  40. 40.
    Schofield K, D’Aquila T, Rimm DL. The cell adhesion molecule, E-cadherin, distinguishes mesothelial cells from carcinoma cells in fluids. Cancer. 1997;81:293–8.CrossRefPubMedGoogle Scholar
  41. 41.
    Saqi A, Yun SS, Yu GH, et al. Utility of CD138 (syndecan-1) in distinguishing carcinomas from mesotheliomas. Diagn Cytopathol. 2005;33:65–70.CrossRefPubMedGoogle Scholar
  42. 42.
    Chu PG, Arber DA, Weiss LM. Expression of T/NK-cell and plasma cell antigens in nonhematopoietic epithelioid neoplasms. An immunohistochemical study of 447 cases. Am J Clin Pathol. 2003;120:64–70.CrossRefPubMedGoogle Scholar
  43. 43.
    O’Connell FP, Pinkus JL, Pinkus GS. CD138 (syndecan-1), a plasma cell marker immunohistochemical profile in hematopoietic and nonhematopoietic neoplasms. Am J Clin Pathol. 2004;121:254–63.CrossRefPubMedGoogle Scholar
  44. 44.
    Llinares K, Escande F, Aubert S, et al. Diagnostic value of MUC4 immunostaining in distinguishing epithelial mesothelioma and lung adenocarcinoma. Mod Pathol. 2004;17:150–7.CrossRefPubMedGoogle Scholar
  45. 45.
    Takezawa C, Takahashi H, Fujishima T, et al. Assessment of differentiation in adenocarcinoma cells from pleural effusion by peripheral airway cell markers and their diagnostic values. Lung Cancer. 2002;38:273–81.CrossRefPubMedGoogle Scholar
  46. 46.
    Mimura T, Ito A, Sakuma T, et al. Novel marker D2-40, combined with calretinin, CEA, and TTF-1: an optimal set of immunodiagnostic markers for pleural mesothelioma. Cancer. 2007;109:933–8.CrossRefPubMedGoogle Scholar
  47. 47.
    Gomez-Fernandez C, Jorda M, Delgado PI, Ganjei-Azar P. Thyroid transcription factor 1: a marker for lung adenocarcinoma in body cavity fluids. Cancer. 2002;96:289–93.CrossRefPubMedGoogle Scholar
  48. 48.
    Zhu W, Michael CW. WT1, monoclonal CEA, TTF1, and CA125 antibodies in the differential diagnosis of lung, breast, and ovarian adenocarcinomas in serous effusions. Diagn Cytopathol. 2007;35:370–5.CrossRefPubMedGoogle Scholar
  49. 49.
    Tan D, Zander DS. Immunohistochemistry for assessment of pulmonary and pleural neoplasms: a review and update. Int J Clin Exp Pathol. 2008;1:19–31.PubMedPubMedCentralGoogle Scholar
  50. 50.
    Agoff SN, Lamps LW, Philip AT, et al. Thyroid transcription factor-1 is expressed in extrapulmonary small cell carcinomas but not in other extrapulmonary neuroendocrine tumors. Mod Pathol. 2000;13:238–42.CrossRefPubMedGoogle Scholar
  51. 51.
    Pomplun S, Wotherspoon AC, Shah G, Goldstraw P, Ladas G, Nicholson AG. Immunohistochemical markers in the differentiation of thymic and pulmonary neoplasms. Histopathology. 2002;40:152–8.CrossRefPubMedGoogle Scholar
  52. 52.
    Suzuki A, Shijubo N, Yamada G, et al. Napsin A is useful to distinguish primary lung adenocarcinoma from adenocarcinomas of other organs. Pathol Res Pract. 2005;201:579–86.CrossRefPubMedGoogle Scholar
  53. 53.
    Dejmek A, Naucler P, Smedjeback A, et al. Napsin A (TA02) is a useful alternative to thyroid transcription factor-1 (TTF-1) for the identification of pulmonary adenocarcinoma cells in pleural effusions. Diagn Cytopathol. 2007;35:493–7.CrossRefPubMedGoogle Scholar
  54. 54.
    El-Hag M, Schmidt L, Roh M, Michael CW. Utility of TTF-1 and Napsin-A in the work up of malignant effusions. Diagn Cytopathol. 2016;44:299–304.CrossRefPubMedGoogle Scholar
  55. 55.
    Chu P, Wu E, Weiss LM. Cytokeratin 7 and cytokeratin 20 expression in epithelial neoplasms: a survey of 435 cases. Mod Pathol. 2000;13:962–72.CrossRefPubMedGoogle Scholar
  56. 56.
    Li HC, Schmidt L, Greenson JK, Chang AC, Myers JL. Primary pulmonary adenocarcinoma with intestinal differentiation mimicking metastatic colorectal carcinoma: case report and review of literature. Am J Clin Pathol. 2009;131:129–33.CrossRefPubMedGoogle Scholar
  57. 57.
    Spriggs AI, Boddington MM. Oat-cell bronchial carcinoma. Identification of cells in pleural fluid. Acta Cytol. 1976;20:525–9.PubMedGoogle Scholar
  58. 58.
    Spieler P, Gloor F. Identification of types and primary sites of malignant tumors by examination of exfoliated tumor cells in serous fluids. Comparison with the diagnostic accuracy on small histologic biopsies. Acta Cytol. 1985;29:753–67.PubMedGoogle Scholar
  59. 59.
    Smith R, Nguyen GK. Unusual cytologic manifestation of small-cell lung cancer in associated pleural effusion. Diagn Cytopathol. 2004;30:266–7.CrossRefPubMedGoogle Scholar
  60. 60.
    Salhadin A, Nasiell M, Nasiell K, et al. The unique cytologic picture of oat cell carcinoma in effusions. Acta Cytol. 1976;20:298–302.PubMedGoogle Scholar
  61. 61.
    Khunamornpong S, Siriaunkgul S, Suprasert P. Cytology of small-cell carcinoma of the uterine cervix in serous effusion: a report on two cases. Diagn Cytopathol. 2001;24:253–5.CrossRefPubMedGoogle Scholar
  62. 62.
    Pereira TC, Saad RS, Liu Y, Silverman JF. The diagnosis of malignancy in effusion cytology: a pattern recognition approach. Adv Anat Pathol. 2006;13:174–84.CrossRefPubMedGoogle Scholar
  63. 63.
    DeLellis RA. The neuroendocrine system and its tumors: an overview. Am J Clin Pathol. 2001;115(Suppl):S5–S16.PubMedGoogle Scholar
  64. 64.
    Chhieng DC, Ko EC, Yee HT, Shultz JJ, Dorvault CC, Eltoum IA. Malignant pleural effusions due to small-cell lung carcinoma: a cytologic and immunocytochemical study. Diagn Cytopathol. 2001;25:356–60.CrossRefPubMedGoogle Scholar
  65. 65.
    Cerilli LA, Ritter JH, Mills SE, Wick MR. Neuroendocrine neoplasms of the lung. Am J Clin Pathol. 2001;116(Suppl):S65–96.PubMedGoogle Scholar
  66. 66.
    Smith-Purslow MJ, Kini SR, Naylor B. Cells of squamous cell carcinoma in pleural, peritoneal and pericardial fluids. Origin and morphology. Acta Cytol. 1989;33:245–53.PubMedGoogle Scholar
  67. 67.
    Huang CC, Michael CW. Cytomorphological features of metastatic squamous cell carcinoma in serous effusions. Cytopathology. 2014;25:112–9.CrossRefPubMedGoogle Scholar
  68. 68.
    Nieto-Llanos S, Vera-Roman JM. Squamous cell carcinoma of the bladder with metastasis diagnosed cytologically in a pleural effusion. Acta Cytol. 1999;43:1191–2.PubMedGoogle Scholar
  69. 69.
    Hoda SA, Rosen PP. Cytologic diagnosis of metastatic penile carcinoma in pleural effusion. Arch Pathol Lab Med. 1992;116:198–9.PubMedGoogle Scholar
  70. 70.
    Gamez RG, Jessurun J, Berger MJ, Pambuccian SE. Cytology of metastatic cervical squamous cell carcinoma in pleural fluid: report of a case confirmed by human papillomavirus typing. Diagn Cytopathol. 2009;37:381–7.CrossRefPubMedGoogle Scholar
  71. 71.
    Pu RT, Pang Y, Michael CW. Utility of WT-1, p63, MOC31, mesothelin, and cytokeratin (K903 and CK5/6) immunostains in differentiating adenocarcinoma, squamous cell carcinoma, and malignant mesothelioma in effusions. Diagn Cytopathol. 2008;36:20–5.CrossRefPubMedGoogle Scholar
  72. 72.
    Ordonez NG. What are the current best immunohistochemical markers for the diagnosis of epithelioid mesothelioma? A review and update. Hum Pathol. 2007;38:1–16.CrossRefPubMedGoogle Scholar
  73. 73.
    Ordonez NG. The diagnostic utility of immunohistochemistry in distinguishing between epithelioid mesotheliomas and squamous carcinomas of the lung: a comparative study. Mod Pathol. 2006;19:417–28.CrossRefPubMedGoogle Scholar
  74. 74.
    Li Q, Bavikatty N, Michael CW. The role of immunohistochemistry in distinguishing squamous cell carcinoma from mesothelioma and adenocarcinoma in pleural effusion. Semin Diagn Pathol. 2006;23:15–9.CrossRefPubMedGoogle Scholar
  75. 75.
    Bassarova AV, Nesland JM, Davidson B. D2-40 is not a specific marker for cells of mesothelial origin in serous effusions. Am J Surg Pathol. 2006;30:878–82.CrossRefPubMedGoogle Scholar
  76. 76.
    Bishop JA, Teruya-Feldstein J, Westra WH, Pelosi G, Travis WD, Rekhtman N. p40 (ΔN063) is superior to p63 for the diagnosis of pulmonary squamous cell carcinoma. Mod Pathol. 2012;25:405–15.CrossRefPubMedGoogle Scholar
  77. 77.
    Alexander M, Chiaffarano J, Zhou F, Cangiarella J, Yee-Chang M, Simsir A. Can p40 (polyclonal) replace p63 (Clone 4A4) in the cytologic diagnosis of pulmonary non-small cell carcinoma? Am J Clin Pathol. 2017;147:580–8.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of PathologyUniversity Hospitals Cleveland Medical Center, Case Western Reserve UniversityClevelandUSA

Personalised recommendations